3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
20
Ovarian Neoplasms
19
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Metastatic Castration-resistant Prostate Cancer
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Glioma
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Osteosarcoma
2
Neoplasms
2
Glioblastoma
2
Cholangiocarcinoma
2
Carcinosarcoma
2
Carcinoma, Endometrioid
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Interventions
Cisplatin
11
Gemcitabine
10
Radiotherapy, Intensity-Modulated
6
Capecitabine
6
Drug Therapy
3
Docetaxel
3
toripalimab
2
spartalizumab
2
pembrolizumab
2
nimotuzumab
2
fludarabine
2
atezolizumab
2
Specimen Handling
2
Platinum
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
Cyclophosphamide
2
Carboplatin
2
Bevacizumab
2
1,2-diaminocyclohexaneplatinum II citrate
2
tislelizumab
1
sintilimab
1
penpulimab
1
olaparib
1
fludarabine phosphate
1
dehydroftorafur
1
camrelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Nasopharyngeal Carcinoma
×
olaparib
×
Clear all
NCT04825990
2026-06-01
POINT
Gruppo Oncologico del Nord-Ovest
Phase 2
Active not recruiting
30 enrolled